Autumn webinar
Thursday October 22nd 2020

Care of the cardiorenal patient:

a focus on RAAS inhibition and management of hyperkalaemia

  • 18.00   Introduction by moderator: Professor Paul Kalra, Consultant Cardiologist, Portsmouth Hospitals NHS Trust
  • 18.10   The importance of potassium homeostasis in cardiorenal patients
    Professor Phil Kalra, Consultant Nephrologist, Salford Royal NHS Foundation Trust
  • 18.30   Treating hyperkalaemia to protect the kidney
    Dr Kieran McCafferty, Consultant Nephrologist, Barts Health NHS Trust and Senior Lecturer, Queen Mary University London
  • 18.50   Treating hyperkalaemia to optimise heart failure treatment
    Dr Patricia Campbell, Consultant Cardiologist and Heart Failure Clinical Lead, Southern Health and Social Care Trust, Northern Ireland
  • 19.10   Discussion: a nursing and pharmacy perspective
    Nurse discussant to be confirmed
    Janine Beezer, Specialist Clinical Pharmacist, City Hospitals, Sunderland
  • 19.30   Webinar close

  • We are able to provide this webinar free of charge for health care professionals. We thank Vifor Pharma UK Ltd. for their award of an unrestricted grant in support of this meeting

What is the webinar about?

We have been listening to your feedback that you would like more case-based and practical learning. We are delighted to be able offer this new webinar, led by experts in the field, that will discuss the practical approach to the management of hyperkalaemia in patients with cardiorenal disease.

This will include the approach to broad-spectrum presentations, from those with potentially life-threatening hyperkalaemia through to the impact of high potassium on the use of prognostically important renin-angiotensin-aldosterone system (RAAS) inhibitors. Using case examples, they will discuss and guide on how to optimally manage such patients and avoid pitfalls that might have adverse consequences to patients. Wherever possible, local pathways will be used and multidisciplinary discussion encouraged.

At the end of the webinar, delegates will have learned/contributed to multidisciplinary discussion around the following topics:

  • The prevalence of hyperkalaemia, its potential causes, presentation, and association with adverse outcomes
  • The prognostic benefit of RAAS inhibitors in patients with chronic heart failure and those with CKD and how hyperkalaemia may influence their prescription
  • The role of potassium binders in managing acute hyperkalaemia and facilitating the use of RAAS inhibitors
  • What national and international guidelines say
  • Review of local guidelines – are they contemporary?
  • Practical advice on how to manage hyperkalaemia in hospital and in the community
  • Multidisciplinary discussion around case histories including special groups, and clinical questions

Sign up for more information

Who can attend?

This webinar can only be attended by healthcare professionals and will be free of charge. It is aimed at anyone treating the cardiorenal patient particularly those working in heart failure, cardiology, nephrology, care of the elderly, general medicine, general practitioners, clinical pharmacists and allied disciplines.


We thank Vifor Pharma UK for their award of an unrestricted educational grant to support this webinar.